A matched comparison of two disappearing stents, one of which dissolves as early as 1 to 2 years after implantation, suggests the two platforms perform equally well and result in similar clinical ...
PARIS, France—A fully bioresorbable drug-eluting stent (DES) shows low late lumen loss and good safety results at 6 months in patients with de novo coronary lesions, according to findings presented ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In patients with single de novo coronary lesions, a ...
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the ...
Elixir Medical placed its first DESolve drug-eluting stent in a patient in Germany since gaining its CE mark last year. The stent is designed to deliver the anti-proliferative drug novolimus and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARIS — The DESolve NX pivotal trial has indicated ...
Elixir Medical's DESolve posted promising results at 12 months.--Courtesy of Elixir Medical Elixir Medical notched more promising results for its DESolve device, keeping vessels clear with low rates ...
SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that on Mon., October 12, ...
21 May 2013, Paris, France: The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results